|
Lupin receives Establishment Inspection Report for its Ankleshwar unit> |
|
Lupin features in Dow Jones Best-in-Class (DJBIC) indices> |
|
Board of Lupin recommends final dividend> |
|
Lupin consolidated net profit rises 89.04% in the March 2026 quarter> |
|
Lupin Q4 PAT jumps 87.72%; EBITDA margin expands 1,070 bps> |
|
Lupin wins USFDA approval for Glycerol Phenylbutyrate oral liquid> |
|
Lupin allots 36,752 equity shares under ESOP> |
|
Lupin to convene board meeting> |
|
Lupin launches diabetes drug in U.S. after FDA nod> |
|
Lupin's New Jersey-based facility gets Form-483 with three observations from US FDA> |